Jan. 13 (Bloomberg) -- The Netherlands’ AEX-Index fell 1.62, or 0.5 percent, to 360.79 at the 5:30 p.m. close in Amsterdam, partly erasing yesterday’s 1.2 percent gain. Belgium’s Bel20 Index increased 0.2 percent to 2,632.68.
The following were among the most active stocks in Benelux markets today. Symbols are in parentheses.
Crucell NV (CRXL NA) advanced 1.5 percent to 24.40 euros, a ninth day of gains. The Dutch vaccine maker that agreed to be bought by Johnson & Johnson has resumed production of pentavalent vaccine at its Shingal plant in South Korea, a spokeswoman for the World Health Organization said. The company halted output last year because of contamination at the site.
Fornix BioSciences NV (FORBI NA) surged 8.6 percent to 2.44 euros, the biggest increase since Oct. 18. The maker of medical aids agreed to sell its Laprolan unit to Rochester Medical Corp. for 10.4 million euros ($14 million) and said Chief Executive Officer Cees Bergman will resign as of April 30.
Royal Philips Electronics NV (PHIA NA) rose 1.4 percent to 24.78 euros, a third straight gain. The world’s biggest lighting company was raised to “outperform” from “underperform” at CA Cheuvreux.
Royal Dutch Shell Plc (RDSA NA) lost 1.5 percent to 25.32 euros, the biggest drop since Nov. 16. Europe’s biggest oil company is concerned that its problems in obtaining an air-quality permit from U.S. authorities will delay its Alaska drilling program by another year, the Financial Times reported, citing an interview with Marvin Odum, president of Shell’s U.S. operations.
TNT NV (TNT NA) added 2.3 percent to 20.77 euros, the highest price in more than four months. The biggest Dutch postal-delivery company agreed to sell its mail business in Belgium and its unaddressed mail business in Italy to their management and private equity company NPM Capital NV. The parcel activities of TNT Post Pakketservice in Belgium are not included in the sale, TNT said.
To contact the reporter on this story: Martijn van der Starre in Amsterdam at email@example.com.
To contact the editor responsible for this story: David Merritt at firstname.lastname@example.org.